Last edition
News about "Alvotech "
Alvotech Reaches Global Settlement on Eylea Biosimilar
The settlement enables Alvotech and its partners to launch the biosimilar from January 1, 2026 in the UK and Canada, from May 1, 2026 in the EEA and other markets outside the US, and in Japan from May 2026 for select indications, expanding to all approved indications from November 1, 2026.
Alvotech | 30/01/2026 | By News Bureau
Alvotech Announces European Launch of Golimumab Biosimilar via Advanz Pharma
Alvotech has announced the European launch of AVT05, the first biosimilar to Simponi (golimumab), through its partner Advanz Pharma, following a tender award from NHS England in the UK to support market introduction.
Alvotech | 22/12/2025 | By News Bureau
Gobivaz, First Simponi Biosimilar, Wins EEA Approval
Alvotech, a global biotechnology company focused on biosimilars, and Advanz Pharma, a UK-based pharmaceutical company specializing in specialty and hospital medicines, announced that the European Commission has granted marketing authorizations for Gobivaz, Alvotech’s biosimilar to Simponi (golimumab).
Alvotech | 23/11/2025 | By Darshana
Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Denosumab
Dr. Reddy’s Laboratories has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for AVT03, a proposed biosimilar to Prolia and Xgeva, moving it closer to potential marketing authorisation in the European Economic Area (EEA).
Alvotech | 24/09/2025 | By Dineshwori | 134
Alvotech and Advanz Pharma Secure European Approval for Eylea Biosimilar Mynzepli
Alvotech and its commercial partner Advanz Pharma have announced that the European Commission has granted marketing authorisation for Mynzepli (aflibercept), a biosimilar to Eylea, available in both pre-filled syringes and vials.
Alvotech | 22/08/2025 | By Dineshwori | 166
Dr. Reddy's Injects INR 565 Crore into Russian Arm
Dr Reddy’s Laboratories Ltd has invested INR 565.4 crore in its Russian arm, Dr Reddy’s Laboratories LLC (DRL Russia), acquiring a 45.19 percent equity stake in the step-down wholly-owned subsidiary.
Alvotech | 29/07/2025 | By Dineshwori | 469
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy